Literature DB >> 22399600

Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma.

Izumi Shimada1, Chieko Iwata, Shino Taga, Hitomi Teramachi, Masaaki Nomura, Ken-Ichi Miyamoto, Hiroyuki Tsuciya, Takashi Wada, Kazuko Kimura, Ryo Matsushita.   

Abstract

Recently, it has been reported that total clearance (CLtot) of vancomycin is significantly higher in patients with malignancies compared to those without malignancies. In the present study, to clarify the mechanism of this enhancement in malignancy, we adopted rat animal models, using chemical carcinogen-induced osteosarcoma, selected lung metastatic lesions (C-SLM), transplanted into thigh muscles. The CLtot and renal clearance (CLr) of vancomycin in the tumor-bearing rats were increased compared to the ones of the control rats without tumor. However, there was no difference in the glomerular filtration rate. The plasma concentrations of interleukin (IL)-1β and IL-6, were elevated in the tumor-bearing rats. When renal proximal tubular epithelial cells (RPTEC) were exposed to IL-1β, IL-6, and tumor necrosis factor (TNF)-α simultaneously, the excretory ratio increased significantly. These findings suggest that tubular excretion or re-absorption by cytokines might be associated with changes in the vancomycin CLtot enhancement in the tumor-bearing rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399600

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.

Authors:  Neil A Miller; Micaela B Reddy; Aki T Heikkinen; Viera Lukacova; Neil Parrott
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

2.  Immunohistochemical localization and pharmacokinetics of the anti-MRSA drug teicoplanin in rat kidney using a newly developed specific antibody.

Authors:  Yutaro Yamamoto; Yuta Yamamoto; Tetsuya Saita; Masashi Shin
Journal:  Med Mol Morphol       Date:  2021-04-17       Impact factor: 2.309

3.  Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.

Authors:  Chie Emoto; Trevor N Johnson; Brooks T McPhail; Alexander A Vinks; Tsuyoshi Fukuda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.